Organigram Acquires Sanity Group Amid Germany’s Cannabis BoomDaily news

Canadian cannabis producer Organigram Global has acquired Germany’s cannabis company Sanity Group to expand its European presence into regulated cannabis markets.

The deal, announced this week, comes as Germany’s medical cannabis industry is gaining momentum and consolidating its position as the largest cannabis market in Europe, appealing to U.S. and Canadian cannabis companies seeking investment opportunities.

The $268 million deal between Organigram and Sanity allows the Canadian company to consolidate its foothold in Germany, Europe’s fastest-growing regulated cannabis market.

Sanity Group reported annual net revenue of $70 million in 2025, up sharply from $11 million in 2023. In the context of this growth, Organigram plans to position the German company as its European hub, given Sanity Group’s European regulatory expertise and network. The German company is also participating in Switzerland’s pilot programs aimed at evaluating the legalization of cannabis in the country.

As well as Germany and Switzerland, the Canadian producer plans to also target other European markets, including Poland, the United Kingdom, and the Czech Republic.

The acquisition is expected to close in the second quarter of 2026, subject to shareholder approval, regulatory clearances in Canada and Germany, and the completion of financing arrangements.

It’s not the first time that Organigram invested in Sanity Group. In 2024, it invested $16.5 million into Sanity Group to secure a strategic foothold in the German and broader European cannabis market.

With this acquisition, however, Germany further consolidates its position as the leading market in the cannabis industry in Europe.

The European country legalized medical cannabis in 2017. It soon attracted foreign investors such as the Canadian-based company Aurora Cannabis.

To read more : Forbes